Sandbox Reserved 1490: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 266: | Line 266: | ||
== Medical relevance == | == Medical relevance == | ||
===•Venous Malformations=== | |||
Venous malformations can cause significant morbidity due to pain, disfigurement and organ dysfunction. Before understanding a lot better the mechanisms leading to this disease, therapies were limited to compression therapy and ablation of malformed veins by sclerotherapy and surgery. | Venous malformations can cause significant morbidity due to pain, disfigurement and organ dysfunction. Before understanding a lot better the mechanisms leading to this disease, therapies were limited to compression therapy and ablation of malformed veins by sclerotherapy and surgery. | ||
| Line 280: | Line 281: | ||
Rapamycin is the first molecular therapy for VMs. | Rapamycin is the first molecular therapy for VMs. | ||
[[Image:lesion area.png]] | |||
===•Cancers=== | |||
Also in malignant cancers, combinations of pro-angiogenic signals activate endothelial cells attracted to the tumor microenvironment, from there enhancing vascular growth. It has previously been suggested that inhibiting angiogenesis by targeting the regulation and cross-interaction of such signals could form the basis of efforts aimed at engineering cancer therapeutics. Unfortunately, that method has only limited clinical benefit. | Also in malignant cancers, combinations of pro-angiogenic signals activate endothelial cells attracted to the tumor microenvironment, from there enhancing vascular growth. It has previously been suggested that inhibiting angiogenesis by targeting the regulation and cross-interaction of such signals could form the basis of efforts aimed at engineering cancer therapeutics. Unfortunately, that method has only limited clinical benefit. | ||
